Difference between revisions of "Adrenocortical Carcinoma"

From OncoWiki
Jump to: navigation, search
(Created page with "=Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy=")
 
m (Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy)
Line 1: Line 1:
 
=Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy=
 
=Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy=
 +
 +
==Mitotane (Lysodren)==
 +
'''There is limited and controversial clinical trial information about adjuvant mitotane use.  See the references for additional case series and expert recommendation articles.'''
 +
 +
===Regimen #1, Wängberg et al. 2010===
 +
Level of Evidence:
 +
<span
 +
style="background:#EEEE00;
 +
padding:3px 6px 3px 6px;
 +
border-color:black;
 +
border-width:2px;
 +
border-style:solid;">Phase II</span>
 +
 +
''Patients started on adjuvant mitotane within 4 weeks of their surgical resection.''
 +
*[[Mitotane (Lysodren)]] 2000 mg PO per day (frequency not specified, such as whether the total daily dose was divided into a few doses throughout the day); within the first 2 to 3 months, [[Mitotane (Lysodren)]] dose was adjusted to achieve a target therapeutic drug level of 14 to 20 mg/L
 +
 +
'''2 to 3-year course'''

Revision as of 02:43, 30 October 2013

Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy

Mitotane (Lysodren)

There is limited and controversial clinical trial information about adjuvant mitotane use. See the references for additional case series and expert recommendation articles.

Regimen #1, Wängberg et al. 2010

Level of Evidence: Phase II

Patients started on adjuvant mitotane within 4 weeks of their surgical resection.

  • Mitotane (Lysodren) 2000 mg PO per day (frequency not specified, such as whether the total daily dose was divided into a few doses throughout the day); within the first 2 to 3 months, Mitotane (Lysodren) dose was adjusted to achieve a target therapeutic drug level of 14 to 20 mg/L

2 to 3-year course